Navigation Links
Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Date:10/27/2009

SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy. These ITT data were presented today in two late breaker oral presentations at the 27th Annual Scientific Meeting of The Obesity Society in Washington, D.C.

Results showed that, on an ITT basis,

  • Approximately 25-33% lost 10% or more of their body weight and 12-16% lost at least 15%; and
  • Obese patients on Contrave demonstrated significant improvements in important markers of cardiometabolic risk including waist circumference, HDL and triglycerides

"The data presented today and on Saturday provide a deeper view of Contrave, and what we believe is a balanced efficacy and safety profile," said Eduardo Dunayevich, M.D., Chief Medical Officer of Orexigen. "These findings should help clinicians assess the potential value of Contrave pharmacotherapy in managing obesity and support our belief that if approved, Contrave could meet the broad range of needs of this patient population by virtue of its efficacy, safety and benefits on key markers of cardiometabolic risk."

Additional data from today's late breaker presentations are outlined in the below table:

    Efficacy Result(+)
                                    COR-I                       COR-II
    --------------------------------------------------------------------------
                               PBO 
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Decline in Global Measles Deaths, Joint News Release: ... and WASHINGTON, Nov. 29, Measles deaths in Africa fell ... 396,000 to 36,000, reaching the,United Nations 2010 goal to ... spectacular gains achieved in Africa helped generate a strong,decline ...
... Nov. 29 AIDS Action Council,joins organizations and individuals ... 20th annual World AIDS Day, December 1, 2007. Since ... awareness,about the HIV/AIDS pandemic and to reinvigorate global, national, ... and 2008 theme of World AIDS Day is leadership. ...
Cached Medicine Technology:Measles Deaths in Africa Plunge by 91% 2Measles Deaths in Africa Plunge by 91% 3Measles Deaths in Africa Plunge by 91% 4AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic 2
(Date:7/11/2014)... Latham, New York (PRWEB) July 11, 2014 ... imaging as an integral part of each patient’s unique ... detailed analysis of the skin’s health and trouble areas ... a personalized aesthetic plan to be established. , Vectra ... during the consultation appointment, Vectra 3D uses a quick ...
(Date:7/11/2014)... Canada (PRWEB) July 11, 2014 ... redefines email management with its unique Netmail Platform, ... Microsoft’s World Partner Conference (WPC), which will be ... from July 13-17, 2014. During the show, Netmail ... an email management solution that consolidates email security, ...
(Date:7/10/2014)... omega 3 fatty acids had healthier joints than those ... fatty acids, according to Duke Medicine researchers. , The ... Diseases (10.1136/annrheumdis-2014-205601) on July 11, 2014, suggest that ... contribute to worsening osteoarthritis. , "Our results suggest that ... factors in the link between obesity and osteoarthritis," said ...
(Date:7/10/2014)... Washington, D.C. (PRWEB) July 10, 2014 ... Alliance for Bangladesh Worker Safety announced today it will ... up to four months’ wages for workers displaced as ... , To date, Alliance inspections have resulted in the ... found in all five cases, raising immediate safety concerns. ...
(Date:7/10/2014)... 10, 2014 Best Drug ... that having family close by during a stay ... whether or not the process is successful, has ... website at http://www.bestdrugrehabilitation.com/success-stories/ . , The new ... testimonials from several Best Drug Rehabilitation graduates who ...
Breaking Medicine News(10 mins):Health News:Williams Rejuva Center Includes Innovative Computer Imaging 2Health News:Netmail Heads to Washington, D.C. to Demonstrate New Release of Netmail 5.3 at WPC 2014 July 13-17, 2014 2Health News:Netmail Heads to Washington, D.C. to Demonstrate New Release of Netmail 5.3 at WPC 2014 July 13-17, 2014 3Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2
... An implantable hemodynamic monitor (IHM) may help to ... with heart failurethose with diastolic heart failure (DHF), reports ... Failure ( http://www.onlinejcf.com/ ), published by Elsevier. , ... of South Carolina, Charleston, the researchers analyzed data on ...
... and aim to strengthen science in selected member states ... EMBC Member States hosting the grantees finance the grants ... Croatia, the Czech Republic, Estonia, Hungary, Poland, Portugal and ... three to five years to help them establish their ...
... of Employees Covered by Plans in Multiple States, Lockheed ... Vantage to Identify Local-Level Opportunities , ... HealthLeaders-InterStudy , the leading provider of managed care ... to coast, Lockheed Martin works with carriers across the ...
... leading neuromodulation company, announced today that beginning January ... by Medicare for incomplete spinal cord injury patients ... Centers for Medicare and Medicaid Services (CMS) establishes ... stimulation (FES) devices including the NESS L300™ Foot ...
... 11 Barr Pharmaceuticals, Inc. (NYSE: ... and Drug Administration (FDA) has accepted for review ... Live Oral Vaccines Biologics License Application (BLA). These ... initiative and demonstrate the Company,s ability to develop, ...
... the emotional health implications of cosmetic surgery are still ... as The Oprah Magazine and Cosmopolitan ... overall worthwhile option for enhancing physical appearance and emotional ... published in Women,s Health Issues journal, is ...
Cached Medicine News:Health News:Implantable monitor may help in managing diastolic heart failure 2Health News:Employer Vantage From HealthLeaders-InterStudy Provides a Snapshot of Both Self- and Fully-Insured Health Benefits to Help Pharmaceutical and Diagnostic Manufacturers Identify Business Opportunities 2Health News:Employer Vantage From HealthLeaders-InterStudy Provides a Snapshot of Both Self- and Fully-Insured Health Benefits to Help Pharmaceutical and Diagnostic Manufacturers Identify Business Opportunities 3Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 2Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 3Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 2Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 3Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 4Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 5Health News:Women's magazines downplay emotional health risks of cosmetic surgery: UBC study 2
300 L, Racked, 96 tips/rack Recommended for 250 and 300 L pipettes....
... tips in a rack for single- ... of Autoclavable Racks: Can be steam ... in racks with an 8 x ... tips is specifically designed to ensure ...
RNase-free Tips...
... tips in a rack for single- ... of Autoclavable Racks: Can be steam ... in racks with an 8 x ... tips is specifically designed to ensure ...
Medicine Products: